

# The Journal of PHARMACOLOGY

## And Experimental Therapeutics

A Publication of the American Society for Pharmacology and Experimental Therapeutics

August 2016

Vol. 358, No. 2

### Contents

#### MINIREVIEW

- S1P Signaling and De Novo Biosynthesis in Blood Pressure Homeostasis 359  
*Anna Cantalupo and Annarita Di Lorenzo*

#### BEHAVIORAL PHARMACOLOGY

- Peripheral Administration of a Long-Acting Peptide Oxytocin Receptor Agonist Inhibits Fear-Induced Freezing 164  
*Meera E. Modi, Mark J. Majchrzak, Kari R. Fonseca, Angela Doran, Sarah Osgood, Michelle Vanase-Frawley, Eric Feysant, Heather McInnes, Ramin Darvari, Derek L. Buhl, and Natasha M. Kablaoui*
- Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice 306  
*Robert A. Owens, Bogna Ignatowska-Jankowska, Mohammed Mustafa, Patrick M. Beardsley, Jenny L. Wiley, Abdulmajeed Jali, Dana E. Selley, Micah J. Niphakis, Benjamin F. Cravatt, and Aron H. Lichtman*
- Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a  $\kappa$ -Opioid Agonist in THC-Treated Mice 334  
*Girish R. Chopda, Viraj Parge, Ganesh A. Thakur, S. John Gatley, Alexandros Makriyannis, and Carol A. Paronis*

#### CARDIOVASCULAR

- Dexamethasone Induces Cardiomyocyte Terminal Differentiation via Epigenetic Repression of Cyclin D2 Gene 190  
*Maresha S. Gay, Chiranjib Dasgupta, Yong Li, Angela Kanna, and Lubo Zhang*
- The Cardenolide Glycoside Acovenoside A Affords Protective Activity in Doxorubicin-Induced Cardiotoxicity in Mice 262  
*Shahira M. Ezzat, Menna El Gaafary, Abeer M. El Sayed, Omar M. Sabry, Zeinab Y. Ali, Susanne Hafner, Michael Schmiech, Lu Jin, Tatiana Syrovets, and Thomas Simmet*
- Synergistic Inhibitory Effect of Rosuvastatin and Angiotensin II Type 2 Receptor Agonist on Vascular Remodeling 352  
*Hui-Yu Bai, Masaki Mogi, Hiroto Nakaoka, Harumi Kan-no, Kana Tsukuda, Xiao-Li Wang, Bao-Shuai Shan, Masayoshi Kukida, Toshifumi Yamauchi, Akinori Higaki, Li-Juan Min, Jun Iwanami, and Masatsugu Horiuchi*

#### CELLULAR AND MOLECULAR

- Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease 282  
*Rebecca A. Barnard, Daniel P. Regan, Ryan J. Hansen, Paola Maycotte, Andrew Thorburn, and Daniel L. Gustafson*

#### CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

- Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344 199  
*Yefim Manevich, Leticia Reyes, Carolyn D. Britten, Danyelle M. Townsend, and Kenneth D. Tew*

#### DRUG DISCOVERY AND TRANSLATIONAL MEDICINE

- Prostaglandin E<sub>2</sub>-Glycerol Ester: In Vivo Evidence for a Distinct Pharmacological Identity from Intraocular Pressure Studies 173  
*David F. Woodward, Neil J. Poloso, and Jenny W. Wang*
- Cerebrospinal Fluid Calbindin D Concentration as a Biomarker of Cerebellar Disease Progression in Niemann-Pick Type C1 Disease 254  
*Allison Bradbury, Jessica Bagel, Maureen Sampson, Nicole Farhat, Wenge Ding, Gary Swain, Maria Prociuk, Patricia O'Donnell, Kenneth Drobatz, Brittney Gurda, Christopher Wassif, Alan Remaley, Forbes Porter, and Charles Vite*
- Treatment with Adenosine Receptor Agonist Ameliorates Pain Induced by Acute and Chronic Inflammation 315  
*Guilherme Carneiro Montes, Nathalia Hammes, Miguel Divino da Rocha, Tadeu Lima Montagnoli, Carlos Alberto Manssour Fraga, Eliezer J. Barreiro, Roberto Takashi Sudo, and Gisele Zapata-Sudo*

## METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

- Differential Regulation of Gene Expression by Cholesterol Biosynthesis Inhibitors That Reduce (Pravastatin) or Enhance (Squalastatin 1) Nonsterol Isoprenoid Levels in Primary Cultured Mouse and Rat Hepatocytes 216  
*Elizabeth A. Rondini, Zofia Duniec-Dmuchowski, Daniela Cukovic, Alan A. Dombkowski, and Thomas A. Kocarek*
- Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers 230  
*Andrea R. Masters, Brandon T. Gufford, Jessica Bo Li Lu, Ingrid F. Metzger, David R. Jones, and Zeruesenay Desta*
- Biliary Elimination of Pemetrexed Is Dependent on Mrp2 in Rats: Potential Mechanism of Variable Response in Nonalcoholic Steatohepatitis 246  
*Anika L. Dzierlenga, John D. Clarke, David M. Klein, Tarun Anumol, Shane A. Snyder, HongYu Li, and Nathan J. Cherrington*
- Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier 294  
*Scott G. Summerfield, Yanyan Zhang, and Houfu Liu*
- Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling, and Simulation 324  
*Cen Guo, Kyunghae Yang, Kenneth R. Brouwer, Robert L. St. Claire, III, and Kim L.R. Brouwer*

## NEUROPHARMACOLOGY

- Pharmacological Effects of a Monoclonal Antibody against 6-Monoacetylmorphine upon Heroin-Induced Locomotor Activity and Pharmacokinetics in Mice 181  
*Anne Marte Sjørusen Kvello, Jannike Mørch Andersen, Elisabeth Leere Øiestad, Jørg Mørland, and Inger Lise Bogen*
- Comparison of (+)- and (–)-Naloxone on the Acute Psychomotor-Stimulating Effects of Heroin, 6-Acetylmorphine, and Morphine in Mice 209  
*Guro Søre Eriksen, Jannike Mørch Andersen, Fernando Boix, Marianne Skov-Skov Bergh, Vigdis Vindenes, Kenner C. Rice, Marilyn A. Huestis, and Jørg Mørland*
- Ontogeny of SERT Expression and Antidepressant-like Response to Escitalopram in Wild-Type and SERT Mutant Mice 271  
*Nathan C. Mitchell, Georgianna G. Gould, Wouter Koek, and Lynette C. Daws*
- Functional Selectivity of CB<sub>2</sub> Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway 342  
*Amey Dhopeswarkar and Ken Mackie*

## LETTERS TO THE EDITOR

- Does Vidarabine Mediate Cardioprotection via Inhibition of AC5? 242  
*Roland Seifert*
- Response to Letter to the Editor on “Does Vidarabine Mediate Cardioprotection via Inhibition of AC5?” 244  
*Claudio A. Bravo, Dorothy E. Vatner, and Stephen F. Vatner*

## NOTICE OF RETRACTION

- Re: Norman AB, Tabet MR, Norman MK, and Tsibulsky VL (2014) Maintained Cocaine Self-Administration Is Determined by Quantal Responses: Implications for the Measurement of Antagonist Potency. *J Pharmacol Exp Ther* 348:311–315; doi:10.1124/jpet.113.210690 241

## ERRATUM

- Correction to: “The Affinity of D<sub>2</sub>-Like Dopamine Receptor Antagonists Determines the Time to Maximal Effect on Cocaine Self-Administration.” 239

□ Supplemental material is available at [jpet.aspetjournals.org](http://jpet.aspetjournals.org).

About the cover: Mrp2<sup>-/-</sup> and NASH-induced alterations in Mrp2 localization. See the article by Dzierlenga et al. ([dx.doi.org/10.1124/jpet.116.234310](https://doi.org/10.1124/jpet.116.234310)).